| DESCRIPTION | - SCHOENWALD RDHARRIS RGURNER D et al., "Ophthalmic bioequivalence of steroid/antibiotic combination formulations", Biopharm Drug Dispos, (19870000), vol. 8, pages 527 - 548 | - |
| DESCRIPTION | - TANG-LIU DDBURKE PJ, "The effect of azone on ocular levobunolol absorption: calculating the area under the curve and its standard error using tissue sampling compartments", Pharm Res, (19880000), vol. 5, pages 238 - 241 | - |
| DESCRIPTION | - LIU et al., "Nanosuspensions of poorly soluble drugs: preparation and development by wet milling", Int. J. of Pharm, (20110000), vol. 411, doi:10.1016/j.ijpharm.2011.03.050, pages 215 - 222, XP055143914 | |
| OPPOSITION | - Abdulganee Memon, P. U. Patel, H. M. Sheth, "Optimization of Formulation Parameters on Ocular Loteprednol Etabonate Nanosuspension by Media Milling Method", International Journal of Pharmaceutical & Biological Archives, (20120101), vol. 4, no. 1, ISSN 0976-3333, pages 46 - 51, XP055643061 | - |
| OPPOSITION | - Anonymous, "Results positive for B+L sub-micron gel formulation of loteprednol etabonate", Ophthalmology Times, Ophthalmology Times, URL: https://www.ophthalmologytimes.com/modern-medicine-feature-articles/results-positive-bl-sub-micron-gel-formulation-loteprednol-etabonate, (20191107), XP055639922 | - |
| OPPOSITION | - D12a - Reply to F&A in D2 of 22 Sept 2023 | - |
| OPPOSITION | - D12b - Submission in parent opposition dated 18 Jan 2024 | - |
| OPPOSITION | - D12c - Response to summons in parent oppo of 11 October 2024 | - |
| OPPOSITION | - D13a - Communication of BoA pursuant to Art 15(1) -Preliminary opinion (in grandparent case) | - |
| OPPOSITION | - D13b - Minutes of oral proceedings of 15 October 2024 | - |
| OPPOSITION | - Gourav Rajoria, Gupta Arushi, "In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery", American Journal of PharmTech Research, (20120101), vol. 2, no. 4, ISSN 2249-3387, pages 24 - 53, XP055643055 | - |
| OPPOSITION | - Prasanna Lakshmi, Giddam Ashwini Kumar, "NANO-SUSPENSION TECHNOLOGY: A REVIEW", International Journal of Pharmacy and Pharmaceutical Sciences, (20100101), vol. 2, no. Suppl.4, pages 35 - 40, XP055643057 | - |
| OPPOSITION | - Rowe Raymond C, Sheskey Paul J, Marian E. Quinn, "Carbomer. Hypromellose. Polycarbophil", Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090101), pages 110 - 509-512, XP093031841 | - |
| OPPOSITION | - Sepassi S., Goodwin D.J., Drake A.F., Holland S., Leonard G., Martini L., Lawrence M.J., "Effect of Polymer Molecular Weight on the Production of Drug Nanoparticles", Journal of pharmaceutical sciences, Elsevier Inc, United States, United States, (20071001), vol. 96, no. 10, doi:10.1002/jps.20979, ISSN 0022-3549, pages 2655 - 2666, XP093031654 | |
| OPPOSITION | - Lisa Schopf, Elizabeth Enlow, Alexey Popov, James Bourassa, Hongming Chen, "Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation", Ophthalmology and Therapy, (20141201), vol. 3, no. 1-2, doi:10.1007/s40123-014-0021-z, ISSN 2193-8245, pages 63 - 72, XP055643059 | |
| OPPOSITION | - Douroumis, D. Fahr, A., "Stable carbamazepine colloidal systems using the cosolvent technique", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20070323), vol. 30, no. 5, doi:10.1016/j.ejps.2006.12.003, ISSN 0928-0987, pages 367 - 374, XP005934190 | |
| OPPOSITION | - Martin J Coffey, Heleen H Decory, Stephen S Lane, "Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop", Clinical Ophthalmology, (20130101), no. 7, doi:10.2147/OPTH.S40588, pages 299 - 312, XP055643072 | |
